$-1.46
(Market cap
$768 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
83.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-2.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-7.4
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.2
-
Face value
--
-
Shares outstanding
32,581,533
Years Aggregate
CFO
$--
EBITDA
$--
Net Profit
$--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Nuvectis Pharma Inc (NVCT)
| 214.3 | 21.4 | 133.8 | 256.8 | 18.3 | -- | -- |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
Nuvectis Pharma Inc (NVCT)
| 39.6 | -34.9 | 11.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Nuvectis Pharma Inc (NVCT)
|
23.7 | 767.6 | 0.0 | -27.9 | -- | -202.6 | -- | 83.7 |
| 84.9 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 72.1 | 10,682.6 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.5 | 13,400.0 | 2,435.9 | 860.6 | 31.0 | 43 | 17 | 7.3 | |
| 105.4 | 12,277.1 | 1,663.7 | 413.6 | 36.3 | 430 | 31.2 | 83.9 | |
| 351.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 533.8 | 11,938.8 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 22.9 | |
| 600.7 | 17,326.2 | 2,782.3 | 491.5 | 21.1 | 110.1 | 36.5 | 39.4 | |
| 344.8 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 144.3 | 9,985.8 | 282.0 | 82.9 | -28.6 | 11.4 | 147 | 11.6 |
Shareholding Pattern
View DetailsAbout Nuvectis Pharma Inc (NVCT)
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug... candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey. Read more
-
Co-Founder, Chairman, CEO & President
Mr. Ron Bentsur M.B.A.
-
Co-Founder, Chairman, CEO & President
Mr. Ron Bentsur M.B.A.
-
Headquarters
Fort Lee, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Nuvectis Pharma Inc (NVCT)
What is the current share price of Nuvectis Pharma Inc (NVCT) Today?
The share price of Nuvectis Pharma Inc (NVCT) is $23.73 (NASDAQ) as of 28-Aug-2026 16:00 EDT. Nuvectis Pharma Inc (NVCT) has given a return of 18.25% in the last 3 years.
What is the current PB & PE ratio of Nuvectis Pharma Inc (NVCT)?
Since, TTM earnings of Nuvectis Pharma Inc (NVCT) is negative, P/E ratio is not available.
The P/B ratio of Nuvectis Pharma Inc (NVCT) is 83.73 times as on 21-Aug-2026, a 1465 premium to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-6.23 |
8.94 |
2024 |
-5.55 |
10.86 |
2023 |
-6.53 |
11.91 |
2022 |
-5.85 |
7.72 |
2021 |
-- |
-- |
What is the 52 Week High and Low of Nuvectis Pharma Inc (NVCT)?
The 52-week high and low of Nuvectis Pharma Inc (NVCT) are Rs 29.28 and Rs 5.55 as of 30-Aug-2026.
What is the market cap of Nuvectis Pharma Inc (NVCT)?
Nuvectis Pharma Inc (NVCT) has a market capitalisation of $ 768 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Nuvectis Pharma Inc (NVCT)?
Before investing in Nuvectis Pharma Inc (NVCT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.